Please login to the form below

Not currently logged in
Email:
Password:

RA Patients

This page shows the latest RA Patients news and features for those working in and with pharma, biotech and healthcare.

AbbVie builds case for arthritis blockbuster-in-waiting upadacitinib

AbbVie builds case for arthritis blockbuster-in-waiting upadacitinib

AbbVie builds case for arthritis blockbuster-in-waiting upadacitinib. Patients with RA reported an improvement in mobility pain on the JAK1 inhibitor. ... AbbVie’s run of positive results for upadacitinib in rheumatoid arthritis continues with new data

Latest news

  • FDA panel undermines Lilly and Incyte’s baricitinib hopes FDA panel undermines Lilly and Incyte’s baricitinib hopes

    The panel gave its blessing to the lower 2mg dose of the JAK inhibitor for adult patients with moderately-to-severely active RA who don’t respond to or cannot tolerate ... Lilly has put a brave face on the outcome, saying that it is “confident that

  • AbbVie’s upadacitinib aces phase III trial AbbVie’s upadacitinib aces phase III trial

    AbbVie’s JAK1 inhibitor upadacitinib has proved more effective than the company’s widely-used TNF blocker Humira in a phase III trial in rheumatoid arthritis patients, without adding to a ... The results were achieved in patients with

  • AbbVie’s JAK inhibitor upadacitinib clears another phase III trial AbbVie’s JAK inhibitor upadacitinib clears another phase III trial

    symptoms and dampening down disease activity in RA patients compared to prior stable methotrexate therapy in the SELECT-MONOTHERAPY study. ... Its earlier trials in RA have compared the drug to placebo on top of methotrexate therapy.

  • Boehringer claims EU okay for Humira biosimilar Boehringer claims EU okay for Humira biosimilar

    Earlier this month Boehringer reported the results of the VOLTAIRE-RA in patients with moderate-to-severe rheumatoid arthritis, showing that Cyltezo was equivalent to $16bn-a-year Humira - the ... Nevertheless, the approval “marks a significant step

  • Boehringer builds evidence base for its Humira biosimilar Boehringer builds evidence base for its Humira biosimilar

    Biosimilars have potential cost benefits to the healthcare system and support affordable access to important biologic medicines for patients living with inflammatory disease like RA.”. ... The CHMP also recommended Cyltezo for paediatric patients, in

More from news
Approximately 0 fully matching, plus 65 partially matching documents found.

Latest Intelligence

  • Pharma deals during February 2014 Pharma deals during February 2014

    Novo Nordisk conducted a phase I safety trial with anti-NKG2A in patients with RA, and will be advancing further development in inflammation, including anti-NKG2D1, which is currently undergoing phase ... DiaPep277R is currently in a phase III

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

  • Lilly and NRAS launch arthritis awareness film campaign Lilly and NRAS launch arthritis awareness film campaign

    The film - called Behind The Smile - coincides with rheumatoid arthritis (RA) awareness week and encourages patients to talk to their healthcare professionals about their struggles and how the disease impacts their ... makes people with RA feel still

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • Biosimilars in 2018: EU doctors’ perceptions of RA drug market

    Biosimilars in 2018: EU doctors’ perceptions of RA drug market. Published in pharmaphorum October 2015 by Laurent Chanroux. ... A panel of around 200 physicians treating RA across Europe (France, Germany, Italy, Spain and the UK) were asked how they

  • Infographic: RA market snapshot

    Infographic: RA market snapshot. An overview of the RA biologic patient. ... Our RA market snapshot will provide you with an introduction to the treatment pathways followed by RA patients treated with biologic agents.

  • Infographic: RA Perceptions

    adalimumab) to continue to lead the market and be used to treat over a third of Rheumatoid Arthritis (RA) patients in three years’ time. ... Download our RA Perceptions: Predicting the future of the European market infographic now ».

  • Biosimilars in 2018: EU doctors’ perceptions of RA drug market

    Biosimilars in 2018: EU doctors’ perceptions of RA drug market. Published in pharmaphorum October 2015 by Laurent Chanroux. ... A panel of around 200 physicians treating RA across Europe (France, Germany, Italy, Spain and the UK) were asked how they

  • Removing the Roadblocks to Effective Patient Treatment

    However, we found RA patients wait an average of 18 months before presenting to a doctor. ... Roadblock 2: Diagnosis – Poor doctor relationship and ongoing anxiety. The relationship RA patients have with their rheumatologist is crucial in getting them

More from PMHub
Approximately 2 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Research Partnership

We are one of the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics